(Reuters) - Novartis said Reclast, or zoledronic acid, had won U.S. approval as the first new treatment in nearly a decade for patients with the disease, which affects about one million people in the United States and around four million worldwide.
The medicine is now approved in more than 50 countries for Paget's disease, Novartis said.
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment